Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer

Oncologist

Volumn 11, Issue 3, 2006, Pages 227-233

  Clemons, Mark ^a   Dranitsaris, George ^a   Cole, David ^b   Gainford, Mary C ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b CANCER CARE ONTARIO   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Bone pain; Breast cancer; Efficacy; Skeletal related events

Indexed keywords

ANALGESIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CODEINE; COLLAGEN TYPE 1; IBANDRONIC ACID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PARACETAMOL; TELOPEPTIDE; ZOLEDRONIC ACID;

AMINO TERMINAL SEQUENCE; ANALGESIA; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER PAIN; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; LOW DRUG DOSE; MORBIDITY; MULTIPLE MYELOMA; OSTEOLYSIS; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCORING SYSTEM; SOLID TUMOR;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOGENESIS; PAIN MEASUREMENT; QUALITY OF LIFE;

EID: 33645089426     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-3-227     Document Type: Review

References (48)

1. Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001;28(suppl 11):75-80.
2. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
3. LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001;28(suppl 11):22-27.
4. Clemons M. Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support. Clin Oncol (R Coll Radiol) 2004;16:108-111.
5. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769-773.
6. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469-475.
7. Ernst DS, Brasher P, Hagen N et al. A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-326.
8. Lipton A, Theriault R, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
9. Tripathy D, Body JJ, Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 2004;26:1947-1959.
10. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
11. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;(2):CD002068.
12. McPartland C, Grosjean L. Treatment of painful bone metastases in Europe and Canada: the role of bisphosphonates. Ann Oncol 2004;15(suppl 3):iii50.
13. Enright K, Clemons M, Chow E. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 2004;12:48-52.
14. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-1411.
15. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
16. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
17. Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-2559.
18. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-1791.
19. Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-3392.
20. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74.
21. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
22. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
23. Rosen L, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
24. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-854.
25. Tripathy D, Lichinitzer M, Lazarev A et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized double-blind, placebo-controlled trial. Ann Oncol 2004;15:743-750.
26. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases.] Bull Cancer 2001;88:701-707. French.
27. van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-498.
28. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25(suppl 1):s10-s18.
29. Anderson PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-1120.
30. Cook RJ, Lawless JF. Marginal analysis of recurrent events and a terminating event. Stat Med 1997;16:911-924.
31. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000;56:554-562.
32. Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-312.
33. Diel IJ, Body JJ, Lichinitser MR et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704-1712.
34. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
35. Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981;34:585-597.
36. Aaronson NK, Ahmedzai S, Bergman B et al. Quality of Life: Assessment, Analysis, and Interpretation. New York: John Wiley, 2000:21.
37. Gainford MC, Dranitsaris G, Clemons M. Systemic treatment of bone metastases from breast cancer: Is it all that it's cracked up to be? J Clin Oncol 2005;23:4802-4803.
38. Clamp A, Danson S, Nguyen H et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004;5:607-616.
39. Brown JE, Thomson CS, Ellis SP et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-2037.
40. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
41. Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
42. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
43. Vinholes JJ, Purohit OP, Abbey ME et al. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-1250.
44. Jagdev SP, Purohit OP, Heatley S et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-1438.
45. Gainford MC, Dranitsaris G, Clemons M et al. Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be? J Clin Oncol 2005;23:4802-4803; author reply 4803.
46. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474.
47. Clemons M, Enright K, Cesta A et al. Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 2004;11:e168-e178.
48. Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5): S270.